David Nierengarten

Stock Analyst at Wedbush

(4.13)
# 529
Out of 5,044 analysts
206
Total ratings
51.79%
Success rate
12.97%
Average return

Stocks Rated by David Nierengarten

Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5$7
Current: $1.50
Upside: +366.67%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90$110
Current: $88.85
Upside: +23.80%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45$70
Current: $36.47
Upside: +91.94%
argenx SE
Oct 13, 2025
Maintains: Outperform
Price Target: $800$880
Current: $825.43
Upside: +6.61%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38$44
Current: $40.43
Upside: +8.83%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $5.07
Upside: +18.34%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $99.68
Upside: +15.37%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $1.98
Upside: +102.02%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $14.20
Upside: +83.10%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $10.72
Upside: +105.32%
Initiates: Outperform
Price Target: $25
Current: $11.31
Upside: +121.04%
Downgrades: Neutral
Price Target: $7
Current: $5.99
Upside: +16.86%
Reiterates: Neutral
Price Target: $8
Current: $27.74
Upside: -71.16%
Reiterates: Outperform
Price Target: $11
Current: $3.01
Upside: +265.45%
Reiterates: Neutral
Price Target: $10
Current: $13.99
Upside: -28.52%
Maintains: Neutral
Price Target: $29$27
Current: $13.57
Upside: +98.97%
Reiterates: Outperform
Price Target: $33
Current: $16.48
Upside: +100.24%
Downgrades: Neutral
Price Target: $8$2
Current: $1.11
Upside: +80.18%
Reiterates: Outperform
Price Target: $31
Current: $17.01
Upside: +82.25%
Maintains: Outperform
Price Target: $87$90
Current: $56.40
Upside: +59.57%
Maintains: Outperform
Price Target: $40$47
Current: $29.20
Upside: +60.96%
Reiterates: Outperform
Price Target: $20
Current: $13.38
Upside: +49.53%
Initiates: Outperform
Price Target: $40
Current: $27.47
Upside: +45.61%
Initiates: Outperform
Price Target: $45
Current: $24.72
Upside: +82.04%
Reiterates: Outperform
Price Target: $10
Current: $2.19
Upside: +356.62%
Initiates: Outperform
Price Target: $18
Current: $4.93
Upside: +265.48%
Reiterates: Neutral
Price Target: $10
Current: $15.89
Upside: -37.07%
Reiterates: Outperform
Price Target: $12
Current: $4.93
Upside: +143.41%
Reiterates: Outperform
Price Target: $57
Current: $26.06
Upside: +118.77%
Upgrades: Outperform
Price Target: $50$175
Current: $10.40
Upside: +1,582.69%
Maintains: Equal-Weight
Price Target: $1,400$500
Current: $3.48
Upside: +14,267.82%
Maintains: Neutral
Price Target: $105$60
Current: $6.43
Upside: +833.13%
Maintains: Outperform
Price Target: $11$19
Current: $8.71
Upside: +118.14%
Maintains: Outperform
Price Target: $71$75
Current: $34.54
Upside: +117.14%
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.80
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $11.18
Upside: -